# OnCo record trogenix (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/trogenix/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "trogenix" ;
  schema:name "Trogenix"@en ;
  schema:description "Trogenix makes a gene therapy that switches on only inside cancer cells, where it makes the cell produce substances that kill it and alert the immune system. Its first treatment, for glioblastoma, the most common aggressive brain tumour in adults, entered a first human trial in May 2026."@en ;
  schema:url <https://onco.cc/companies/trogenix/>, <https://trogenix.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://trogenix.com/>, <https://trogenix.com/trogenix-announces-95-million-series-a-financing/>, <https://trogenix.com/news-events/> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-situ-vaccination/> .